MNPR insider trading
NasdaqCM HealthcareMonopar Therapeutics — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Monopar Therapeutics
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Company website: www.monopartx.com
MNPR insider activity at a glance
FilingIQ has scored 250 insider transactions for MNPR since Dec 18, 2019. The most recent filing in our index is dated Mar 31, 2026.
Across the full history, 19 open-market purchases
and 12 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MNPR insider trades is 68.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MNPR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for MNPR?
- FilingIQ tracks 250 Form 4 insider transactions for MNPR (Monopar Therapeutics), covering filings from Dec 18, 2019 onwards. 7 of those were filed in the last 90 days.
- Are MNPR insiders net buyers or net sellers?
- Across the full Form 4 history for MNPR, 19 transactions (8%) were open-market purchases and 12 (5%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MNPR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is MNPR in?
- Monopar Therapeutics (MNPR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $370.82M.
Methodology & sources
Every MNPR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.